Physician profile
Whitney S Graybill
NPI 1851550305
$81,387.67
in general payments reported to CMS, 2019-2025
14 companies · $38K in 2025
The $38K reported for 2025 was more than what 96% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,507 · 2020: $6,782 · 2021: $4,047 · 2022: $13K · 2023: $7,245 · 2024: $6,440 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Consulting Fee: $10K · Travel and Lodging: $8,667 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,800 · Food and Beverage: $1,008 · Education: $64.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,575.00 |
| Consulting Fee | $10,475.00 |
| Travel and Lodging | $8,667.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,800.00 |
| Food and Beverage | $1,008.16 |
| Education | $64.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37,839.86 | 2022-2025 | |
| Glaxosmithkline, LLC. | $22,196.87 | 2021-2025 | Zejula |
| Astrazeneca Pharmaceuticals Lp | $12,590.02 | 2019-2024 | Lynparza |
| Tesaro, INC. | $5,434.64 | 2019 | |
| Clovis Oncology, INC. | $1,700.00 | 2020 | |
| Medtronic, INC. | $1,158.25 | 2021-2024 | Signia |
| Myriad Genetic Laboratories, INC. | $232.54 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $118.63 | 2025 | Keytruda |
| Genentech USA, INC. | $53.24 | 2019 | |
| Medtronic Vascular, INC. | $36.89 | 2020 | |
| Ethicon US, LLC | $26.73 | 2023 | Stratafix, Enseal X1 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Graybill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.